Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorder SALT LAKE CITY, Feb. 23, 2022 (GLOBE ...
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan ...
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a ...
Hi! I am a psychiatric mental health nurse practitioner with more than 20 years' experience. I work with young children, adolescents, adults and seniors. My goal is to help you or your family member ...
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...